VALONTAN 10CPR RIV 100MG

VALONTAN ADULTS 100 MG COMPRESENT RIVES

active ingredients

Each coated tablet contains: Active ingredient Dimenhydrate 100 mg Excipient with known effects: each coated tablet contains 16 mg of sucrose. For the full list of excipients, see paragraph 6.1.

Excellent

Sucrose, colloidal silica, magnesium stearate, corn starch. Coating components: acrylic resin (Eudragit), talc.

Therapeutic indications

Prevention and treatment of nausea, vomiting and dizziness, proper to naupatie (sea, car, train, plane).

Contraindications

Hypersensitivity to the active ingredient, to other antihistamines, or to any of the excipients. Contraindicated in children and teenagers. Contraindicated during pregnancy and nursing.

Population

Adults In naupatie (sea, car, train, plane), nausea and vomiting can be controlled with a single dose of half a tablet VALONTAN Adults (50 mg), whose effect lasts approximately for 4 hours; this dose, if necessary, can be repeated, for prevention purposes, every 4 hours (3 tablets in 24 hours). Do not exceed the recommended doses. Do not use for prolonged treatments.

Conservation

None.

Warnings

The use of antihistamines at the same time to certain antibiotics or other ototoxic drugs can mask the first signs of ototoxicity, which can only be revealed when the damage is irreversible. Use with caution in subjects suffering from glaucoma, prostatic hypertrophy, other urinary retention syndromes, intestinal obstruction, arterial hypertension, cardiovascular disease, bronchial asthma, chronic bronchitis or emphysema, hyperthyroidism. The medicinal product may exacerbate convulsive disorders. It should therefore be used with great caution in subjects suffering from epilepsy. VALONTAN Adults contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactosis mal absorption, or isomaltase sucrasis failure, should not take this medicine.

Interactions

During the treatment avoid the contemporary use of alcoholic beverages and antidepressant, hypnotic, sedative or tranquilizer drugs, in order to prevent any additive phenomena of sedation (see also paragraph 4.7).

Effects

Following treatment with VALONTAN Adults reported the following side effects:

Organic system classification according to MedDRA	Most common side effects	Frequently unwanted effects	Less frequent side effects
Disorders of metabolism and nutrition		Anorexia
Psychiatric disorders			Insomnia, Euforia
Diseases of the nervous system	Sedazione, Sonnolenza	Cefa	Vertigo, Tremori, Convulsioni
Pathologies of the eye		Disorders of acceptance
Heart disease			Tachycardia
Vascular diseases			Hypotension
Gastrointestinal diseases		Dryness of the bundles, Nausea
Pathologies of skin and subcutaneous tissue		Sensitivity, Skin reaction on an allergic basis
Kidney and urinary pathologies		Disorders of urination
Systemic pathologies and conditions for administration			Austria

Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

Overdosing

In case of overdose, consult your doctor immediately. Drowsiness is the most usual symptom of hyperdose. Toxic doses can produce: convulsion, coma and respiratory depression. In case of symptomatic therapy. When necessary, respiratory assistance.

VALONTAN Adults are contraindicated during pregnancy and nursing (see paragraph 4.3). In patients breastfeeding it is necessary to decide whether to give up feeding the child and start treatment or, vice versa, continue breastfeeding avoiding the administration of the product.

Source: Farmadati